LENG9

Across TCGA pan-cancer cohorts, LENG9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LENG9 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LENG9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LENG9 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where LENG9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.642	1.000	.004	18	view →
PDAC	OS	Tertile	IV	0.916	0.231	.024	6	view →
LUAD	OS	Median	II,III,IV	0.999	0.863	.039	5	view →
GBM	OS	Median	All	0.395	0.644	.033	2	view →
HNSC	OS	Median	III,IV	0.561	0.768	.019	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LENG9–CCRCC (DFS)

Open the CCRCC breakdown →